<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Laser-Assisted Intradermal Delivery of Adjuvant-Free Vaccines Targeting XCR1 + Dendritic Cells Induces Potent Antitumoral Responses</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Dorothea</forename><surname>Terhorst</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Centre d&apos;Immunologie de Marseille-Luminy</orgName>
								<orgName type="institution">UM2 Aix-Marseille Universite ´</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">INSERM U1104</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Centre National de la Recherche Scientifique</orgName>
								<orgName type="institution" key="instit2">Unite ´Mixte de Recherche</orgName>
								<address>
									<postCode>7280, 13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="laboratory">Jebsen Centre for Influenza Vaccine Re-search</orgName>
								<orgName type="institution">Charite ´University Medicine</orgName>
								<address>
									<postCode>10117</postCode>
									<settlement>Berlin</settlement>
									<country>Germany; { K.G</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">University of Oslo</orgName>
								<address>
									<postCode>0424</postCode>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Even</forename><surname>Fossum</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><surname>Baranska</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Centre d&apos;Immunologie de Marseille-Luminy</orgName>
								<orgName type="institution">UM2 Aix-Marseille Universite ´</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">INSERM U1104</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Centre National de la Recherche Scientifique</orgName>
								<orgName type="institution" key="instit2">Unite ´Mixte de Recherche</orgName>
								<address>
									<postCode>7280, 13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Samira</forename><surname>Tamoutounour</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Centre d&apos;Immunologie de Marseille-Luminy</orgName>
								<orgName type="institution">UM2 Aix-Marseille Universite ´</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">INSERM U1104</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Centre National de la Recherche Scientifique</orgName>
								<orgName type="institution" key="instit2">Unite ´Mixte de Recherche</orgName>
								<address>
									<postCode>7280, 13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Camille</forename><surname>Malosse</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Centre d&apos;Immunologie de Marseille-Luminy</orgName>
								<orgName type="institution">UM2 Aix-Marseille Universite ´</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">INSERM U1104</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Centre National de la Recherche Scientifique</orgName>
								<orgName type="institution" key="instit2">Unite ´Mixte de Recherche</orgName>
								<address>
									<postCode>7280, 13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mattia</forename><surname>Garbani</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Molecular Allergol-ogy</orgName>
								<orgName type="institution" key="instit1">Swiss Institute of Allergy and Asthma Research</orgName>
								<orgName type="institution" key="instit2">University of Z€ urich</orgName>
								<address>
									<postCode>7270</postCode>
									<settlement>Davos</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Reinhard</forename><surname>Braun</surname></persName>
							<affiliation key="aff7">
								<orgName type="laboratory">Pantec Biosolutions</orgName>
								<address>
									<postCode>9491</postCode>
									<settlement>Ruggell</settlement>
									<country key="LI">Liechtenstein</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elmira</forename><surname>Lechat</surname></persName>
							<affiliation key="aff7">
								<orgName type="laboratory">Pantec Biosolutions</orgName>
								<address>
									<postCode>9491</postCode>
									<settlement>Ruggell</settlement>
									<country key="LI">Liechtenstein</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Reto</forename><surname>Crameri</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Molecular Allergol-ogy</orgName>
								<orgName type="institution" key="instit1">Swiss Institute of Allergy and Asthma Research</orgName>
								<orgName type="institution" key="instit2">University of Z€ urich</orgName>
								<address>
									<postCode>7270</postCode>
									<settlement>Davos</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bjarne</forename><surname>Bogen</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Center for Immune Regulation</orgName>
								<orgName type="department" key="dep2">Institute of Immunology</orgName>
								<orgName type="institution">University of Oslo</orgName>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution">Oslo University Hospital Rikshospitalet</orgName>
								<address>
									<postCode>0424</postCode>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Sandrine</forename><surname>Henri</surname></persName>
							<email>henri@ciml.univ-mrs.fr</email>
							<affiliation key="aff1">
								<orgName type="department">Centre d&apos;Immunologie de Marseille-Luminy</orgName>
								<orgName type="institution">UM2 Aix-Marseille Universite ´</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">INSERM U1104</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Centre National de la Recherche Scientifique</orgName>
								<orgName type="institution" key="instit2">Unite ´Mixte de Recherche</orgName>
								<address>
									<postCode>7280, 13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Dr</roleName><forename type="first">Bernard</forename><surname>Malissen</surname></persName>
							<email>bernardm@ciml.univ-mrs.fr</email>
							<affiliation key="aff1">
								<orgName type="department">Centre d&apos;Immunologie de Marseille-Luminy</orgName>
								<orgName type="institution">UM2 Aix-Marseille Universite ´</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">INSERM U1104</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Centre National de la Recherche Scientifique</orgName>
								<orgName type="institution" key="instit2">Unite ´Mixte de Recherche</orgName>
								<address>
									<postCode>7280, 13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">The American Association of Immunologists, Inc</orgName>
								<address>
									<addrLine>Suite 650</addrLine>
									<postCode>1451, 20852</postCode>
									<settlement>Rockville Pike, Rockville</settlement>
									<region>MD</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Centre d&apos;Immunologie de Marseille-Luminy</orgName>
								<orgName type="institution">Parc Scientifique de Luminy</orgName>
								<address>
									<postCode>13288, Cedex 9</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Laser-Assisted Intradermal Delivery of Adjuvant-Free Vaccines Targeting XCR1 + Dendritic Cells Induces Potent Antitumoral Responses</title>
					</analytic>
					<monogr>
						<idno type="ISSN">0022-1767</idno>
					</monogr>
					<idno type="MD5">0CAF0B65E0F8F4538A67D9F874556232</idno>
					<idno type="DOI">10.4049/jimmunol.1500564</idno>
					<note type="submission">Received for publication March 10, 2015. Accepted for publication April 15, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:46+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>B6, C57BL/6J</term>
					<term>CTV, CellTrace Violet</term>
					<term>DC, dendritic cell</term>
					<term>LC, Langerhans cell</term>
					<term>LN, lymph node</term>
					<term>moDC, monocyte-derived DC</term>
					<term>P.L.E.A.S.E., Precise Laser Epidermal System</term>
					<term>STING, stimulator of IFN genes</term>
					<term>XCR1, XC-chemokine receptor 1</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The development of vaccines inducing efficient CD8 + T cell responses is the focus of intense research.</s><s>Dendritic cells (DCs) expressing the XCR1 chemokine receptor, also known as CD103 + or CD8a + DCs, excel in the presentation of extracellular Ags to CD8 + T cells.</s><s>Because of its high numbers of DCs, including XCR1 + DCs, the skin dermis is an attractive site for vaccine administration.</s><s>By creating laser-generated micropores through the epidermis, we targeted a model protein Ag fused to XCL1, the ligand of XCR1, to dermal XCR1 + DCs and induced Ag-specific CD8 + and CD4 + T cell responses.</s><s>Efficient immunization required the emigration of XCR1 + dermal DCs to draining lymph nodes and occurred irrespective of TLR signaling.</s><s>Moreover, a single intradermal immunization protected mice against melanoma tumor growth in prophylactic and therapeutic settings, in the absence of exogenous adjuvant.</s><s>The mild inflammatory milieu created in the dermis by skin laser microporation itself most likely favored the development of potent T cell responses in the absence of exogenous adjuvants.</s><s>The existence of functionally equivalent XCR1 + dermal DCs in humans should permit the translation of laser-assisted intradermal delivery of a tumor-specific vaccine targeting XCR1 + DCs to human cancer immunotherapy.</s><s>Moreover, considering that the use of adjuvants in vaccines is often associated with safety issues, the possibility of inducing protective responses against melanoma tumor growth independently of the administration of exogenous adjuvants should facilitate the development of safer vaccines.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>D</head><p><s>endritic cells (DCs) capture Ags in body barriers and migrate to lymph nodes (LNs), where they trigger the differentiation of Ag-specific, naive T cells into effector T cells.</s><s>Recent studies, based on ontogeny and global geneexpression profiles, showed that a few DC subsets exist in the mouse.</s><s>Functional specialization probably accounts for their existence, and they can be aligned with functionally equivalent human subsets <ref type="bibr" target="#b0">(1)</ref><ref type="bibr" target="#b1">(2)</ref><ref type="bibr" target="#b2">(3)</ref><ref type="bibr" target="#b3">(4)</ref>.</s><s>The XC-chemokine receptor 1 (XCR1) binds to a single ligand known as XCL1 and is expressed by a DC subset that was characterized previously by the expression of CD8a, CD207, or CD103 <ref type="bibr" target="#b4">(5)</ref><ref type="bibr" target="#b5">(6)</ref><ref type="bibr" target="#b6">(7)</ref>.</s><s>Mouse XCR1 + DCs excel in crosspresentation of self-Ags <ref type="bibr" target="#b7">(8,</ref><ref type="bibr" target="#b8">9)</ref> and dead tumor cell-associated Ags, a feature that is probably owing to their expression of the C-type lectin CLEC9A (also known as DNGR1), a receptor for damaged and apoptotic cell materials <ref type="bibr" target="#b9">(10,</ref><ref type="bibr" target="#b10">11)</ref>.</s><s>Targeting Ags to DCs has been used successfully to generate strong immune responses and recently entered clinical trials <ref type="bibr" target="#b11">(12)</ref>.</s><s>For instance, when delivered i.v. in the presence of adjuvant, Ags chemically or genetically conjugated to CLEC9A Ab or to XCL1 elicit potent cytotoxic CD8 + T cell responses capable of destroying tumors <ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref><ref type="bibr" target="#b14">(15)</ref><ref type="bibr" target="#b15">(16)</ref><ref type="bibr" target="#b16">(17)</ref>.</s></p><p><s>Owing to its high numbers of DCs, the skin is a particularly attractive site for vaccine administration.</s><s>However, for ease of application, most of the skin vaccines that are used in massvaccination programs are not delivered into the epidermis or the dermis but into the hypodermis, which is a layer of fat and connective tissue just below the dermis with poorly characterized APCs.</s><s>Such s.c.</s><s>delivery bypasses the rich network of DCs present in the epidermis and dermis.</s><s>Several delivery systems were developed recently to exploit the potential of dermal DCs.</s><s>For example, vaccination with microneedles, made from a biocompatible polymer, has been used to introduce influenza virus vaccine <ref type="bibr" target="#b17">(18)</ref> or live recombinant human adenovirus type 5 <ref type="bibr" target="#b18">(19)</ref> into the dermis.</s><s>These approaches generated robust humoral and cellular immune responses.</s><s>A portable laser, the Precise Laser Epidermal System (P.L.E.A.S.E), also was used to create micropores in the stratum corneum, the superficial impermeable layer of the skin, and the epidermis, allowing topically applied Ags to diffuse into the dermis and to induce potent immune responses <ref type="bibr" target="#b19">(20)</ref>.</s></p><p><s>Vaccibodies are homodimeric chimeric proteins consisting of a targeting unit, a hinge domain, and an Ag moiety <ref type="bibr" target="#b20">(21)</ref>.</s><s>XCL1based vaccibodies were developed recently to target Ags to XCR1 + DCs <ref type="bibr" target="#b21">(22)</ref>.</s><s>When used in a DNA format, flu hemagglutinin-containing vaccibodies improved CD8 + T cell responses and protected mice against a lethal challenge with influenza A virus <ref type="bibr" target="#b21">(22)</ref>.</s><s>In the current study, we used the P.L.E.A.S.E.</s><s>portable laser to deliver XCL1-based vaccibodies, in a protein format, within the dermis and demonstrated that they permit the harnessing of unique T cell immunostimulatory properties of XCR1 + dermal DCs.</s><s>Using B16F10 (B16), a highly aggressive metastatic and poorly immunogenic melanoma and its OVA-expressing variant (B16-OVA), we demonstrated the in vivo antitumor efficacy of a single round of laser-assisted, dermal delivery of OVA-containing XCL1-based vaccibodies in both prophylactic and therapeutic settings and in the absence of intentionally added adjuvants.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mice</head><p><s>Mice were used at 8-12 wk of age, housed under specific pathogen-free conditions, and handled in accordance with French and European directives.</s><s>All mice were maintained on a B6 background.</s><s>OT-I mice <ref type="bibr" target="#b22">(23)</ref>, OT-II mice (24), Ccr7 2/2 mice (25), Myd88 2/2 Trif Lps2/Lps2 mice deficient in both MyD88 and Trif (Ticam1) (called Myd88 2/2 Trif 2/2 mice hereafter) <ref type="bibr" target="#b25">(26)</ref>, and Xcr1 tm1Dgen mice (Xcr1-bGal, called Xcr1 2/2 mice hereafter) (6) were described previously.</s><s>C57BL/6J (B6) mice were purchased from Janvier (Le Genest-Saint-Isle, France).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Isolation of skin DCs, monocytes, monocyte-derived DCs, and macrophages</head><p><s>To extract skin myeloid cells, ears were split into dorsal and ventral parts and incubated with a solution of PBS containing 1 mg/ml Dispase (Roche) for 2 h at 37˚C or overnight at 4˚C.</s><s>The dorsal and ventral parts were then cut into small pieces and incubated for 90 min at 37˚C with RPMI 1640 culture medium containing 1 mg/ml DNase and 1 mg/ml Collagenase IV (Worthington Biochemical).</s><s>The resulting single-cell suspension was subjected to centrifugation on a Percoll gradient (Amersham-Pharmacia).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characterization of skin myeloid cells</head><p><s>Myeloid cells from the skin were characterized by flow cytometry, as previously described <ref type="bibr" target="#b26">(27)</ref>.</s><s>Briefly, single-cell suspensions were prepared by enzymatic digestion and gentle dissociation of ear skin.</s><s>After excluding dead cells (SYTOX + ), T cells (CD3 + ), NK cells (CD161c + ), B cells (CD19 + ), and neutrophils (Ly-6G + ), the remaining CD45 + MHCII + CD11c + cells contain Langerhans cells (LCs; CD11b + CD24 + ), XCR1 + (CD11b 2 CD24 + ) dermal DCs, and CD11b + CD24 low dermal cells.</s><s>Analysis of CD11b + CD24 low dermal cells for the expression of Ly-6C and CD64 permits the identification of CD11b + DCs on the basis of their Ly-6C 2 CD64 2 phenotype.</s><s>The remaining CD11b + CD24 low dermal cells include monocytes, monocyte-derived DCs (moDCs), and macrophages.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Flow cytometry</head><p><s>Cells were stained and analyzed using a FACS LSR II system with DIVA software (BD Biosciences).</s><s>Cell viability was evaluated using SYTOX (Invitrogen), according to the manufacturer's protocol.</s><s>Anti-NK1.1 (PK136), anti-CD3 (17A2), anti-Ly-6G (1A8), anti-CD19 (6D5), and anti-CD64 (X54-5/7.1)</s><s>were from BioLegend.</s><s>Anti-CD11c (N418), anti-MHC class II (I-A/I-E) (M5/114.15.2), anti-CD45.2</s><s>(104), anti-CD45.1 (A20), anti-CD24 (M1/69), and anti-CD5 (53-7.3)</s><s>were from eBioscience.</s><s>Anti-Ly-6C (AL21), anti-CD4 (RM4-5), and anti-CD8a (53-6.7)</s><s>were from BD Pharmingen.</s><s>Prior to the analysis of monocytes, macrophages, DCs, B cells, T cells, NK cells, and neutrophils were systematically gated out using a "dump-channel" corresponding to cells positive for B220, CD3, NK1.1, or Ly-6G.</s><s>Analysis was performed using FlowJo software (TreeStar).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generation of vaccibodies</head><p><s>XCL1-OVA vaccibodies contain the XCL1 chemokine and the OVA Ag linked through a dimerization domain consisting of the hinge and CH3 domain of human IgG3.</s><s>XCL1-OVA vaccibodies were produced in HEK293E cells and purified using an affinity column containing an Ab directed against the vaccibody dimerization domain <ref type="bibr" target="#b21">(22)</ref>.</s><s>After elution, vaccibodies were dialyzed against PBS.</s></p><p><s>Laser-assisted skin microporation and vaccibodies or OVA application on the skin A P.L.E.A.S.E.</s><s>portable laser developed by Pantec Biosolutions (28) was used with the following settings: fluence: 11.9 J/cm 2 , pulse duration: 75 ms, RepRate: 200 Hz, pulses/pore: 2, pore array size: 14 mm 2 , and pore density: and LCs (CD11b + CD24 + ).</s><s>Analysis of CD45 + CD11b + CD24 low cells (right panel) for the expression of Ly-6C and CD64 required to identify CD11b + DCs (Ly-6C 2 CD64 2 ) and monocytes, moDCs, and macrophages (Ly-6C low to high CD64 low to high ).</s><s>(C) Single-cell suspensions prepared from the ear skin of B6 (WT) and Xcr1 2/2 mice were incubated with XCL1-mCherry vaccibodies and analyzed by flow cytometry, as described in (B).</s><s>Shaded line graphs represent control, XCL1-mCherry-unstained cell samples.</s><s>Numbers represent the percentage of XCL1-mCherry + cells (n = 3).</s><s>8%.</s><s>P.L.E.A.S.E.-assisted skin microporation was performed on the ear of anesthetized mice, and 20 ml sterile PBS, sterile PBS containing 1.5 mg (low) or 3.1 mg (high) OVA, or sterile PBS containing 2.5 mg (low) or 5 mg (high) XCL1-OVA was applied evenly on the microporated ear surface.</s><s>The PBS solution percolated inside the micropores in ,10 min.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histology</head><p><s>For histological analysis, ears were harvested after laser poration and embedded in paraffin.</s><s>Sections (5 mm) were stained with H&amp;E for microscopic examination.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preparation of CellTrace Violet-labeled T cells</head><p><s>OT-I and OT-II T cells were isolated from pooled LNs and spleen of OT-I or OT-II mice kept on a Rag-2 2/2 -B6 (CD45.1)</s><s>background using Dynal CD8 + and CD4 + T Cell Negative Isolation Kits (Invitrogen), respectively.</s><s>Purity was determined by staining with CD4, CD8, CD5, and TCR Va2.</s><s>For labeling with CellTrace Violet (CTV; Molecular Probes), purified OT-I and OT-II T cells were resuspended in PBS containing 2.5 mM CTV for 20 min at 37˚C.</s><s>A total of 10 6 CTV-labeled OT-I and OT-II T cells was adoptively transferred into the specified mice.</s><s>At the indicated times, single-cell suspensions were prepared from the auricular LNs draining the immunized ears, and OT-I and OT-II T cells were analyzed by FACS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In vivo cytotoxicity assay</head><p><s>Splenocytes from B6 mice were pulsed with the SIINFEKL peptide or left untreated and labeled with a low (0.25 mM) or high (2.5 mM) dose of CTV.</s><s>A total of 10 7 splenocytes of each preparation was adoptively transferred into mice that had been immunized for 6 d.</s><s>Thirty-six hours later, a singlecell suspension was prepared from spleen, and the ratio of CTV high /CTV low cells was determined by FACS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tumor model</head><p><s>Mice were injected s.c.</s><s>into the flank with 10 5 B16-OVA or B16 melanoma cells <ref type="bibr" target="#b27">(29)</ref>.</s><s>Tumor size was assessed 14-16 d later using a caliper.</s><s>Determining tumor volume after sacrificing the mice and careful dissection of the tumor mass constituted a more accurate and reproducible measure of tumor size compared with the measurement of s.c.</s><s>tumor volume on live mice with a caliper.</s><s>To adhere to institutional ethical guidelines, mice inoculated with B16 melanoma cells were sacrificed 14 d (therapeutic protocol) or 16 d (prophylactic protocol) after tumor inoculation.</s><s>The presence of T cells infiltrating the tumor was assessed after enzymatic treatment of tumor mass with collagenase 2 (Worthington) and Percoll gradient (Amersham-Pharmacia).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intracellular staining</head><p><s>T cells harvested from the tumor mass were incubated for 6 h at 37˚C in the presence of PMA (5 ng/ml) and ionomycin (250 ng/ml).</s><s>Monensin (GolgiStop; BD Pharmingen) was added to the suspension for the last 5 h.</s><s>Cells were stained with anti-CD5, anti-CD4, anti-CD8, and H-2 K b tetramers loaded with the SIINFEKL peptide (iTAg MHC tetramers; Beckman Coulter) and then permeabilized using the Cytofix/Cytoperm kit (BD Biosciences).</s><s>Intracellular cytokines were detected by staining with anti-IFN-g (XMG1.2;</s><s>BD Pharmingen).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>The magnitude of the experimental effect observed in preliminary experiments led to the estimation of the proper sample size in each experiment.</s><s>Because some of the experimental groups did not pass the D'Agostino and Pearson omnibus normality test, a Mann-Whitney U test was used to assess the statistical significance within the different immunization settings.</s><s>Exact probability values are shown in the figures.</s><s>A p value .</s><s>0.05 was considered nonsignificant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Laser-assisted, intradermal delivery of XCL1-based vaccibodies permits the specific targeting of XCR1 + dermal DCs Prior to targeting XCR1 + dermal DCs in situ, we characterized the specificity of the XCL1-based vaccibodies on single-cell suspen-FIGURE 2. Laser-assisted, dermal delivery of XCL1-mCherry vaccibodies permits the specific targeting of XCR1 + dermal DCs in vivo.</s><s>(A) Macroscopic view of a mouse ear microporated with the P.L.E.A.S.E.</s><s>portable laser at 11.9 J/cm 2 (n = 3).</s><s>(B) H&amp;E staining of a representative ear section after laser microporation at 11.9 J/cm 2 .</s><s>Stratum corneum (S), epidermis (E), dermis (D), and cartilage (C) areas of the ear are indicated.</s><s>The position of a micropore is indicated by an arrow.</s><s>Scale bar, 100 mm (n = 3).</s><s>(C) Twenty-four hours after application of XCL1-mCherry vaccibodies (3.8 mg in 20 ml of PBS) on laser microporated ear skin of B6 (WT) and Xcr1 2/2 mice, single-cell suspensions were prepared from the ear skin, and the binding of XCL1-mCherry to XCR1 + DCs, LCs, CD11b + DCs, monocytes, moDCs, and macrophages was analyzed by flow cytometry, as in Fig. <ref type="figure" target="#fig_0">1B</ref>.</s><s>Shaded line graphs represent control, XCL1-mCherry-unstained cell samples.</s><s>Numbers represent the percentage of XCL1-mCherry + cells (n = 3).</s></p><p><s>The Journal of Immunology sions prepared by enzymatic digestion and gentle dissociation of ear skin.</s><s>For that purpose, the antigenic moiety of XCL1-based vaccibodies was replaced by mCherry, a red monomeric fluorescent protein (Fig. <ref type="figure" target="#fig_0">1A</ref>) that allows binding specificity to be assessed by flow cytometry.</s><s>By combining CD24 and CD11b expression, XCR1 + dermal DCs (also known as CD103 + or CD8a + DCs) and LCs can be readily identified among the CD45 + MHCII + CD11c + cells found in the skin of the ear (Fig. <ref type="figure" target="#fig_0">1B</ref>) <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b26">27)</ref>.</s><s>Analysis of CD45 + CD11b + CD24 low dermal cells for the expression of Ly-6C and CD64 further identified CD11b + DCs on the basis of their Ly-6C 2 CD64 2 phenotype <ref type="bibr" target="#b26">(27)</ref>.</s><s>The remaining CD45 + CD11b + CD24 low non-DCs included monocytes, moDCs, and macrophages (Fig. <ref type="figure" target="#fig_0">1B</ref>).</s><s>XCL1-mCherry vaccibodies specifically stained XCR1 + DCs, whereas no staining was observed on cells isolated from the ear of mice deficient in XCR1 (Fig. <ref type="figure" target="#fig_0">1C</ref>).</s></p><p><s>To target XCL1-based vaccibodies to XCR1 + dermal DCs in a needle-free manner, we used a P.L.E.A.S.E.</s><s>portable laser.</s><s>Application on the mouse ear skin using 75 ms pulse duration with two pulses/pore and an energy of 11.9 J/cm 2 resulted in the formation of an array of micropores via laser ablation (Fig. <ref type="figure">2A</ref>).</s><s>Histological analysis of ear sections indicated that the stratum corneum and the epidermis were removed, whereas the integrity of the dermis was preserved (Fig. <ref type="figure">2B</ref>).</s><s>Therefore, the regimen chosen created pores whose depth was compatible with topically applied XCL1-based vaccibodies reaching the dermis.</s><s>Analysis of single-cell suspension prepared from ear skin 24 h after laserassisted delivery of XCL1-mCherry vaccibodies showed that ∼15% of XCR1 + dermal DCs were stained; using Xcr1 2/2 mice, this staining was shown to depend on XCR1 expression (Fig. <ref type="figure">2C</ref>).</s><s>Therefore, the combination of laser microporation and XCL1based vaccibodies permits targeting of XCR1 + dermal DCs in a specific and needle-free manner.</s></p><p><s>Twenty-four hours after laser microporation, analysis of the ear skin showed a mild inflammation that occurred irrespective of the application of XCL1-OVA vaccibodies and involved infiltrates made of neutrophils and CD45 + CD11b + CD24 low cells (Supplemental Fig. <ref type="figure" target="#fig_0">1A, 1B</ref>).</s><s>Resolution of the different subsets present among the infiltrating CD45 + CD11b + CD24 low cells <ref type="bibr" target="#b5">(6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b26">27)</ref> showed that they were dominated by Ly-6C high monocytes and moDCs.</s><s>In contrast, 24 h after laser microporation the numbers of LCs, XCR1 + and CD11b + dermal DCs, and macrophages remained unchanged (Supplemental Fig. <ref type="figure" target="#fig_0">1C</ref>).</s><s>Therefore, despite the rapid infiltration of laser microporated skin by neutrophils, monocytes, and moDCs, the topically applied XCL1-based vaccibodies still succeeded at targeting XCR1 + dermal DCs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>XCL1-OVA vaccibodies are more effective at eliciting T cell responses on a per-molecule basis than free OVA</head><p><s>To test whether targeting XCR1 + dermal DCs with Ag-loaded XCL1-based vaccibodies induced the activation of Ag-specific T cells in vivo, the model Ag OVA was inserted into XCL1based vaccibodies.</s><s>Mice were adoptively transferred with CTVlabeled OT-I CD8 + T cells and OT-II CD4 + T cells; they express a TCR specific for SIINFEKL, an OVA-derived peptide presented by H-2K b , and for an OVA-derived peptide presented by H2-A b , respectively.</s><s>One day later, the ears of the mice were subjected to laser-assisted microporation and topical application of XCL1-OVA vaccibodies.</s><s>To compare the potency of the XCL1-OVA formulation with that of free OVA and, thus, determine the gain resulting from targeting OVA to XCR1 + DCs through XCL1-OVA vaccibodies, ears also were subjected to laser-assisted microporation and topical application of OVA in amounts equimolar to that present in XCL1-OVA vaccibodies.</s><s>Three days after immunization, single-cell suspensions were prepared from ear-draining auricular LNs, and the extent of OT-I and OT-II cell proliferation was determined by CTV dilution (Fig. <ref type="figure" target="#fig_1">3A</ref>).</s><s>XCL1-OVA vaccibodies triggered a higher proliferation of OT-I and OT-II cells than did free OVA (Fig. <ref type="figure" target="#fig_1">3B</ref>).</s><s>Quantification of the data confirmed that XCL1-OVA vaccibodies were, on a per-molecule basis, 15 times more effective at eliciting CD8 + T cell proliferation and 3 times more effective at eliciting CD4 + T cell proliferation than was free OVA (Fig. <ref type="figure" target="#fig_1">3C</ref>).</s><s>When the same experiments were repeated with Xcr1 2/2 mice, the beneficial effect observed following XCL1-OVA treatment was lost: the magnitude of proliferation induced with XCL1-OVA was comparable to that of OVA (Fig. <ref type="figure" target="#fig_1">3C</ref>).</s></p><p><s>The XCL1 chemokine present in XCL1-OVA vaccibodies was shown to retain its chemotactic function <ref type="bibr" target="#b21">(22)</ref>.</s><s>Therefore, the higher potency noted for XCL1-OVA Abs compared with OVA may not result from the targeting of OVA to XCR1 + DCs but from the ability of XCL1 to promote encounters between XCR1 + DCs and T cells <ref type="bibr" target="#b4">(5,</ref><ref type="bibr" target="#b28">30)</ref>.</s><s>However, coadministration of OVA and XCL1 in free forms and in amounts similar to those used in XCL1-OVA treatment resulted in levels of T cell proliferation similar to those elicited by OVA alone (Fig. <ref type="figure" target="#fig_1">3C</ref>).</s><s>Therefore, the physical linkage between OVA and XCL1 provided by the vaccibody format was essential to maximize the immunogenic potential of XCR1 + dermal DCs, and it is likely that XCR1 merely functioned as a target for delivery of Ag.</s></p><p><s>T cell responses elicited by laser-assisted intradermal delivery of XCL1-OVA vaccibodies require migratory XCR1 + DCs and occur in a MyD88-Trif-independent manner Skin DCs capture incoming Ags and after 2-5 d, depending on the DC subset, migrate to skin-draining LNs to elicit T cell responses <ref type="bibr" target="#b29">(31)</ref><ref type="bibr" target="#b30">(32)</ref><ref type="bibr" target="#b31">(33)</ref>.</s><s>However, Ags that enter the dermis and are small enough to penetrate the lymphatic vessels can reach the LN subcapsular sinus in a free form <ref type="bibr" target="#b32">(34)</ref>.</s><s>Such lymph-borne Ags can be captured by DCs that line the subcapsular sinus <ref type="bibr" target="#b33">(35)</ref>.</s><s>This led to a more rapid generation of effector T cell responses, independent of skinderived migratory DCs.</s><s>DC-free drainage of skin-delivered Ags is amplified during needle-based, intradermal, and s.c.</s><s>immunization as a result of the excessive interstitial hydrostatic pressure created by fluid injections <ref type="bibr" target="#b32">(34)</ref>.</s><s>To evaluate whether T cell responses elicited by laser-assisted, intradermal delivery of XCL1-OVA vaccibodies required the migration of skin-derived XCR1 + DCs, rather than the capture of free XCL1-OVA vaccibodies by the XCR1 + DCs that permanently reside in skin-draining LNs (36), we used Ccr7 2/2 mice, in which the CCR7-dependent migration of DCs from the skin to the draining LNs is impaired <ref type="bibr" target="#b24">(25)</ref>.</s><s>Analysis of T cell responses of wild-type and Ccr7 2/2 mice 3 d after immunization showed that OT-I and OT-II responses were reduced 10-20-fold in the absence of CCR7 (Supplemental Fig. <ref type="figure">2A, 2B</ref>).</s><s>Therefore, CD4 + and CD8 + T cell activation induced by laser-assisted intradermal delivery of XCL1-OVA vaccibodies is primarily due to migration of OVA-presenting XCR1 + dermal DCs to draining LNs.</s><s>Consistent with the view that following laserassisted intradermal delivery free XCL1-OVA vaccibodies do not diffuse away from the ear immunization site via the blood, adoptively transferred OT-I and OT-II T cells present in the spleen and in LNs that drain territories distinct from the ear showed no sign of proliferation (Supplemental Fig. <ref type="figure">2C, 2D</ref>).</s></p><p><s>Although XCL1-OVA vaccibodies were affinity purified and reconstituted in endotoxin-free PBS prior to delivery, we determined whether the extensive proliferation of Ag-specific T cells observed after targeting XCR1 + dermal DCs with XCL1-OVA vaccibodies persisted in Myd88 2/2 Trif 2/2 double-deficient mice that are deprived of two adaptors used in all of the TLR signaltransduction networks.</s><s>Laser-assisted, intradermal delivery of XCL1-OVA vaccibodies in Myd88 2/2 Trif 2/2 double-deficient mice resulted in levels of OT-I and OT-II T cell proliferation similar to those elicited in wild-type mice (Supplemental Fig. <ref type="figure" target="#fig_1">3</ref>).</s><s>Therefore, T cell responses triggered by laser-assisted intradermal delivery of XCL1-OVA vaccibodies require the migration of dermal XCR1 + DCs and occur irrespective of TLR signals.</s><s>Intradermal delivery of XCL1-OVA vaccibodies protects mice against melanoma tumor growth in prophylactic and therapeutic settings</s></p><p><s>The B16-OVA melanoma is not rejected by immune-competent syngeneic B6 mice unless they have been subjected to prophylactic or therapeutic immunization.</s><s>To evaluate the capacity of laser-assisted, intradermal delivery of XCL1-OVA vaccibodies to inhibit the growth of B16-OVA tumors, B6 mice were inoculated s.c. in the flank with B16-OVA cells (Fig. <ref type="figure" target="#fig_2">4A</ref>).</s><s>Three days later, the ears of the mice were subjected to laser-assisted, dermal delivery of XCL1-OVA vaccibodies, and tumor growth was monitored 14 d after tumor inoculation.</s><s>For comparison, control mice received PBS or equimolar amounts of free OVA.</s><s>A single intradermal immunization with a low or a high dose of XCL1-OVA vaccibodies significantly suppressed tumor growth compared with the OVA and PBS groups, and tumor growth was further reduced with the high dose of XCL1-OVA vaccibodies (Fig. <ref type="figure" target="#fig_2">4B</ref>).</s><s>To investigate the prophylactic effects on tumor growth induced by laser-assisted intradermal XCL1-OVA immunization, B6 mice were immunized with XCL1-OVA vaccibodies and inoculated s.c. with B16-OVA tumor cells 30 d later (Fig. <ref type="figure" target="#fig_2">4C</ref>).</s><s>Monitoring tumor growth 16 d after tumor inoculation showed that XCL1-OVA vaccibodies significantly slowed tumor growth compared with OVA and PBS (Fig. <ref type="figure" target="#fig_2">4D</ref>).</s><s>As expected, XCL1-OVA vaccibodies induced an OVAspecific immunity, and mice immunized with XCL1-OVA vaccibodies were not able to control the growth of B16 melanoma that did not express OVA (Fig. <ref type="figure">5A</ref>).</s><s>Moreover, the capacity of XCL1-OVA vaccibodies to inhibit B16-OVA tumor growth was dependent on the expression of XCR1 (Fig. <ref type="figure">5B</ref>).</s></p><p><s>To assess whether the reduction in melanoma tumor growth observed upon treatment with XCL1-OVA vaccibodies was asso-ciated with the induction of endogenous, Ag-specific CD8 + T cells, wild-type and Xcr1 2/2 mice were immunized via laser-assisted intradermal delivery of XCL1-OVA vaccibodies.</s><s>Six days after immunization, the magnitude of OVA-specific T cell cytotoxicity was assessed using an in vivo cytotoxic assay (Fig. <ref type="figure">5C</ref>).</s><s>XCL1-OVA vaccibodies induced a significant T cell cytotoxicity compared with PBS or OVA treatment.</s><s>The absence of detectable lysis in Xcr1 2/2 mice indicates that such T cell cytotoxicity was dependent on the expression of XCR1.</s><s>Moreover, analysis of the CD8 + and CD4 + T cells that infiltrated the B16-OVA tumor mass of mice treated with XCL1-OVA vaccibodies showed that they were capable of producing IFN-g (Fig. <ref type="figure">5D</ref>).</s><s>In contrast, OVA treatment did not induce IFN-g + T cells over PBS control, a finding consistent with the observation that OVA treatment was unable to slow tumor growth (Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>In addition, staining of CD8 + T cells that infiltrated the regressing B16-OVA tumor mass found in XCL1-OVA-treated mice with H-2 K b tetramers loaded with the OVA-derived, SIINFEKL peptide showed an ∼100-fold increase in the numbers of OVA-specific, IFN-g2producing CD8 + T cells compared with OVA-treated mice (Supplemental Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>Therefore, laser-assisted, intradermal delivery of XCL1-OVA vaccibodies induced antitumoral responses that can be correlated with the presence of OVA-specific IFNg + CD8 + T cells in the regressing tumor mass.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In the current study, we show that, by creating laser-generated micropores in the stratum corneum and epidermis of the skin, it is possible to target XCL1-OVA vaccibodies to XCR1 + dermal DCs and to induce Ag-specific CD8 + and CD4 + effector T cells.</s><s>This process required migration of XCR1 + dermal DCs to draining LNs FIGURE 5. Laser-assisted, dermal delivery of XCL1-OVA vaccibodies induces potent OVA-specific effector T cells in a XCR1-dependent manner.</s><s>(A) B6 mice were inoculated s.c. with B16-OVA or B16 melanoma and immunized 3 d later with XCL1-OVA vaccibodies using laser-assisted, dermal delivery.</s><s>On day 11 after immunization, the volume of the tumor developing in each mouse was determined.</s><s>Volumes are shown for each individual mouse and the mean (horizontal bar) is indicated for each condition (n = 3).</s><s>(B) B6 (WT) and Xcr1 2/2 mice were inoculated s.c. with B16-OVA melanoma and immunized 3 d later with XCL1-OVA vaccibodies using laser-assisted, dermal delivery.</s><s>On day 11 after immunization, the tumor volume was determined for each mouse.</s><s>Volumes are shown for each individual mouse, and the mean (horizontal line) is indicated for each condition (n = 3).</s><s>(C) B6 (WT) and Xcr1 2/2 mice were subjected to laser-assisted, dermal delivery of 20 ml of PBS (control) or PBS containing OVA (1.5 mg) or XCL1-OVA (2.5 mg) vaccibodies.</s><s>On day 6, mice were injected with CFSE-labeled target cells to quantitate the induced OVA-specific cytotoxicity in vivo (see Materials and Methods).</s><s>The percentage of specific lysis is shown for each individual mouse, and the mean (horizontal line) is indicated for each condition (n = 3).</s><s>(D) B6 mice were inoculated s.c. with B16-OVA or B16 and immunized 3 d later with 20 ml of PBS (control) or PBS containing OVA (1.5 mg) or XCL1-OVA (2.5 mg) vaccibodies using laser-assisted, dermal delivery.</s><s>On day 11 after immunization, the tumor mass of each mouse was excised, and the percentage of IFN-g + cells was determined among tumor-infiltrating CD8 + and CD4 + T cells.</s><s>Data are shown for each individual mouse, and the mean (horizontal line) is indicated for each condition (n = 2).</s><s>and occurred irrespective of TLR signals.</s><s>Moreover, a single intradermal immunization with XCL1-OVA vaccibodies protected mice against melanoma tumor growth in both prophylactic and therapeutic settings and in the absence of intentionally added adjuvant.</s><s>Whether Ag targeting to DC results in tolerance or immunity depends on parameters such as the immunogenicity of the targeting Ab ( <ref type="formula">16</ref>) and the coadministration of adjuvants <ref type="bibr" target="#b35">(37,</ref><ref type="bibr" target="#b36">38)</ref>.</s><s>Adjuvants are intended to trigger the pattern-recognition receptors that are expressed by the targeted DCs and that are normally used to detect invading microorganisms or endogenous "danger" signals.</s><s>In contrast to other studies that targeted XCR1 + DCs via needle-based, i.v., or cutaneous injection <ref type="bibr" target="#b13">(14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b37">39)</ref>, we achieved Ag-specific protection against the B16-OVA melanoma in the absence of intentionally added adjuvant.</s><s>Moreover, TLR signals were dispensable for the Ag-specific T cell responses resulting from laser-assisted intradermal delivery of XCL1-OVA vaccibodies.</s><s>The mode of Ag delivery itself by skin laser microporation most likely explains such a marked difference in adjuvant requirement.</s><s>The fractional Er:YAG laser operating in the P.L.E.A.S.E.</s><s>portable laser creates microcoagulated areas in the skin that include dying cells <ref type="bibr" target="#b38">(40)</ref>.</s><s>STING (stimulator of IFN genes) is a protein that resides in the endoplasmic reticulum of many cells, including DCs.</s><s>It cooperates with the nucleotidyltransferase cGAS to trigger the production of type I IFNs in response to the presence of pathogen-or self-derived DNA in the cytosol.</s><s>It was shown recently that XCR1 + DCs contribute to trigger T cell responses against tumors in a STING-dependent manner <ref type="bibr" target="#b39">(41)</ref><ref type="bibr" target="#b40">(42)</ref><ref type="bibr" target="#b41">(43)</ref>.</s><s>XCR1 + DCs use STING to sense the self-DNA released by dying tumor cells <ref type="bibr" target="#b42">(44)</ref> and, as a result, produce type I IFN that contributes to boost their Ag-presenting function and T cell costimulatory properties.</s><s>Therefore, it is likely that, in our model, the death of keratinocytes induced by laser microporation acts as a STING-dependent adjuvant.</s><s>We also noted that laser microporation triggers a rapid infiltration of the treated skin area with granulocytes, monocytes, and moDCs.</s><s>Therefore, altogether, the adventitious phenomena resulting from skin laser microporation itself create an inflammatory milieu that most likely favors the development of potent T cell immune responses in the absence of exogenous adjuvants.</s><s>In a mouse model, a rat anti-CLEC9A Ab used to deliver OVA to XCR1 + DCs induced CD4 + T cell and humoral responses against OVA in the absence of adjuvant ( <ref type="formula">16</ref>), a property resulting from the presence of helper epitopes on the rat Ab that were recognized as foreign by the mouse immune system.</s><s>Along the same line, the dimerization unit derived from human IgG3 domains and present in vaccibodies likely contributes to enhance mouse immune responses against the antigenic cargo (21).</s><s>Finally, considering that the use of adjuvants in vaccines is often associated with safety issues, the ability to induce protective responses against melanoma tumor growth independently of the administration of exogenous adjuvants should facilitate the development of safer vaccines.</s></p><p><s>Migratory DCs originating from tissues such as the skin and intestine are thought to "instruct" Ag-specific naive T cells in a way that confers them with a propensity to home to the tissue from which the migratory DCs originated <ref type="bibr" target="#b43">(45)</ref>.</s><s>Such tropism allows primed T cells to exert their effector functions in the tissue subjected to the Ag challenge.</s><s>When injected i.v., Ag-conjugated anti-CLEC9A Abs target the XCR1 + DCs that permanently reside in the spleen and, thereby, initiate T cell responses in this organ <ref type="bibr" target="#b13">(14)</ref>.</s><s>In contrast, following laser-assisted, intradermal delivery of XCL1-OVA vaccibodies, the onset of T cell responses depended on the migration of XCR1 + dermal DCs and remained limited to the skin-draining LNs.</s><s>Whether skin-derived XCR1 + DCs confer to Ag-specific T cells a skin tropism superior to that elicited by spleen-resident XCR1 + DCs constitutes an important issue when treating conditions such as cutaneous melanoma.</s><s>Although the T cell priming resulting from laser-assisted, intradermal delivery of XCL1-OVA vaccibodies is limited to the LN draining the treated skin area, a systemic T cell response ensued that was capable of protecting against cutaneous melanoma developing at a site distant from the one used for immunization.</s><s>When translated to humans, this approach should limit the systemic side effects resulting from the administration of i.v.</s><s>vaccines while achieving systemic protective immunity.</s></p><p><s>In conclusion, using laser-assisted intradermal delivery and a model Ag fused to the XCL1 chemokine, we showed that it is possible to target dermal XCR1 + DCs and harness their crosspresentation capacity.</s><s>Although the efficiency of many vaccines relies on multiple rounds of administration in the presence of adjuvants, we showed that a single intradermal immunization with XCL1-based vaccibodies is sufficient to protect mice against melanoma tumor growth in the absence of exogenous adjuvants.</s><s>Therefore, topic, laser-assisted intradermal delivery of Ags targeting XCR1 + DCs constitutes a promising route for the delivery of vaccines.</s><s>In humans, XCR1 expression defines a DC subset that shows a similar anatomical distribution to mouse XCR1 + DCs and is endowed with cross-presentation capacity <ref type="bibr" target="#b28">(30,</ref><ref type="bibr" target="#b44">(46)</ref><ref type="bibr" target="#b45">(47)</ref><ref type="bibr" target="#b46">(48)</ref>, a feature that should facilitate the translation of the present mouse model to human settings.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc><div><p><s>FIGURE 1. XCL1-mCherry vaccibodies specifically target XCR1 + dermal DCs in vitro.</s><s>(A) XCL1based vaccibodies are homodimeric chimeric proteins consisting of the XCL1 chemokine, a dimerization unit made of the hinge and CH3 domain of human IgG3, and an Ag moiety, such as OVA.</s><s>To determine whether XCL1-based vaccibodies specifically bind to XCR1 + dermal DCs, the antigenic moiety was replaced by mCherry, a red monomeric fluorescent protein.</s><s>(B) Flow cytometry analysis of CD45 + cells from the ear skin of mice after gating out granulocytes, T cells, B cells, and NK cells.</s><s>Analysis of CD45 + MHCII + CD11c + cells (left panel) for the expression of CD24 and CD11b required to identify XCR1 + DCs (CD11b 2 CD24 + ) and LCs (CD11b + CD24 + ).</s><s>Analysis of CD45 + CD11b + CD24 low cells (right panel) for the expression of Ly-6C and CD64 required to identify CD11b + DCs (Ly-6C 2 CD64 2 ) and monocytes, moDCs, and macrophages (Ly-6C low to high CD64 low to high ).</s><s>(C) Single-cell suspensions prepared from the ear skin of B6 (WT) and Xcr1 2/2 mice were incubated with XCL1-mCherry vaccibodies and analyzed by flow cytometry, as described in (B).</s><s>Shaded line graphs represent control, XCL1-mCherry-unstained cell samples.</s><s>Numbers represent the percentage of XCL1-mCherry + cells (n = 3).</s></p></div></figDesc><graphic coords="3,240.89,485.37,288.14,77.90" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 3 .</head><label>3</label><figDesc><div><p><s>FIGURE 3. Laser-assisted, dermal delivery of XCL1-OVA vaccibodies triggers potent OVA-specific CD4 + and CD8 + T cell proliferative responses.</s><s>(A) Timeline of adoptive transfer of CTV-labeled OT-I and OT-II T cells, laser-assisted dermal Ag delivery, and analysis of OT-I and OT-II T cell proliferation within auricular, ear-draining LNs.</s><s>(B) Single-cell suspensions were prepared from ear-draining, auricular LNs from B6 (WT) and Xcr1 2/2 mice that received OT-I and OT-II T cells and were immunized by applying 20 ml of PBS containing OVA (3.1 mg), XCL1-OVA vaccibodies (5 mg), XCL1 (1.8 mg) plus OVA (3.1 mg), or PBS alone as a control to laser-microporated ears.</s><s>Seventy-two hours after Ag delivery, the extent of proliferation was determined by CTV dilution.</s><s>Numbers represent the percentage of divided T cells (n = 3).</s><s>(C) Quantification of data shown in (B).</s><s>Absolute numbers of proliferating OT-I and OT-II T cells recovered per auricular LN from B6 (WT) and Xcr1 2/2 mice; each symbol represents an individual mouse.</s><s>The mean (horizontal line) is indicated for each condition.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 4 .</head><label>4</label><figDesc><div><p><s>FIGURE 4. Laser-assisted, dermal delivery of XCL1-OVA vaccibodies protects mice against melanoma tumor growth in therapeutic and prophylactic settings.</s><s>(A) Timeline of the therapeutic setting involving s.c.</s><s>inoculation of the B16-OVA melanoma, laser-assisted dermal delivery of PBS, OVA, or XCL1-OVA vaccibodies, and tumor volume measurement.</s><s>(B) A cohort of mice, treated as in (A) with 20 ml of PBS containing OVA (low dose: 1.5 mg; high dose: 3.1 mg) or XCL1-OVA vaccibodies (low dose: 2.5 mg or high dose: 5.0 mg), was analyzed for tumor volume.</s><s>Control mice were treated with 20 ml of PBS.</s><s>Tumor volume is shown for each individual mouse, and the mean (horizontal line) is indicated for each condition; one representative experiment of three is shown.</s><s>(C) Timeline of the prophylactic setting involving laser-assisted, dermal delivery of 20 ml of PBS or PBS containing OVA (1.5 mg) or XCL1-OVA vaccibodies (2.5 mg); s.c.</s><s>inoculation of the B16-OVA melanoma; and tumor volume measurement.</s><s>(D) A cohort of mice, treated as specified in (C) with OVA or XCL1-OVA, was analyzed for tumor volume.</s><s>Control mice were treated with 20 ml of PBS.</s><s>Tumor volume is shown for each individual mouse, and the mean (horizontal line) is indicated for each condition (n 5 3).</s><s>n.s., nonsignificant.</s></p></div></figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">by guest on May 17, 2022 http://www.jimmunol.org/ Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">The Journal of Immunology</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We thank M. Dalod, A.-M. Schmitt-Verhulst, and C. Coscia for discussions, R.J. Driscoll for the Xcr1 tm1Dgen mice, L. Alexopoulou for the Myd88 2/2 Trif Lps2/Lps2 mice, M. Dalod for importing the Xcr1 tm1Dgen mice, and L. Chasson for assistance with histology.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The origins and functions of dendritic cells and macrophages in the skin</title>
		<author>
			<persName><forename type="first">B</forename><surname>Malissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tamoutounour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Henri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="417" to="428" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Ontogeny and functional specialization of dendritic cells in human and mouse</title>
		<author>
			<persName><forename type="first">M</forename><surname>Haniffa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Collin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ginhoux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Immunol</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="1" to="49" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Re(de)fining the dendritic cell lineage</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Satpathy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Albring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Murphy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1145" to="1154" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting</title>
		<author>
			<persName><forename type="first">M</forename><surname>Merad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sathe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Helft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mortha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="563" to="604" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Dorner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Dorner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Opitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uttler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hutloff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Mages</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ranke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaefer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="823" to="833" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8a+ type</title>
		<author>
			<persName><forename type="first">K</forename><surname>Crozat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tamoutounour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Vu Manh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fossum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Luche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ardouin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guilliams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Azukizawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Malissen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="page" from="4411" to="4415" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bachem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hartung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uttler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hegemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Plantinga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mazzini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stoitzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gurka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">214</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Henri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Poulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tamoutounour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ardouin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guilliams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bovis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Devilard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Viret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Azukizawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kissenpfennig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Malissen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="page" from="189" to="206" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Crosspresentation of viral and self antigens by skin-derived CD103+ dendritic cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bedoui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Whitney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waithman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Eidsmo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wakim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Caminschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Allan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wojtasiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shortman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Carbone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="488" to="495" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Czabotar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Policheni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Caminschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kitsoulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Tullett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Robin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Brammananth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Van Delft</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="646" to="657" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ahrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zelenay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sancho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Han C</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Feest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fletcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Durkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Postigo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Skehel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="635" to="645" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Dhodapkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sznol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Carvajal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Keohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Sanborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lutzky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Powderly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="232" to="251" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement</title>
		<author>
			<persName><forename type="first">I</forename><surname>Caminschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Proietto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ahmet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kitsoulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Shin</forename><surname>Teh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rizzitelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vremec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Van Dommelen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="3264" to="3273" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">P</forename><surname>Joffre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sancho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zelenay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reis E Sousa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1255" to="1265" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1</title>
		<author>
			<persName><forename type="first">E</forename><surname>Hartung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bachem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Reeg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hutloff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Weise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giesecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Henn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="page" from="1069" to="1079" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ahmet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Brooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Kent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>De Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Salazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sousa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Shortman</surname></persName>
		</author>
		<author>
			<persName><surname>Lahoud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="854" to="864" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sancho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moura ˜o-Sa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´</forename></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">P</forename><surname>Joffre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Rogers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Pennington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Carlyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Reis E Sousa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Invest</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="2098" to="2110" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Dissolving polymer microneedle patches for influenza vaccination</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Koutsonanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Del Pilar Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Zarnitsyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Murthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Compans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Skountzou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Prausnitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="915" to="920" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays</title>
		<author>
			<persName><forename type="first">V</forename><surname>Bachy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hervouet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Becker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chorro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Carlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Papagatsias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Barbaroux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benlahrech</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="3041" to="3046" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Transcutaneous vaccination via laser microporation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hessenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kitzm€ Uller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Weinberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Krautgartner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hauser-Kronberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Malissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">N</forename><surname>Kalia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Control. Release</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="391" to="399" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Fredriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bogen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="1797" to="1805" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus</title>
		<author>
			<persName><forename type="first">E</forename><surname>Fossum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Grødeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Terhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Tveita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Vikse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mjaaland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Henri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Malissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bogen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Immunol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="624" to="635" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">T cell receptor antagonist peptides induce positive selection</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Hogquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Jameson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Howard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Bevan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Carbone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="17" to="27" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Defective TCR expression in transgenic mice constructed using cDNA-based alpha-and betachain genes under the control of heterologous regulatory elements</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Barnden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Allison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Heath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Carbone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="34" to="40" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fo ¨rster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schubel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Breitfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kremmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Renner-M€ Uller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lipp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="23" to="33" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Skin-draining lymph nodes contain dermis-derived CD103(2) dendritic cells that constitutively produce retinoic acid and induce Foxp3(+) regulatory T cells</title>
		<author>
			<persName><forename type="first">M</forename><surname>Guilliams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Crozat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Henri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tamoutounour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grenot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Devilard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bovis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Alexopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Malissen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="1958" to="1968" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tamoutounour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guilliams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sanchis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Terhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Malosse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pollet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ardouin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Luche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sanchez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1365" to="1374" />
			<date type="published" when="2012">2013. 2012</date>
		</imprint>
	</monogr>
	<note>Allergy</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Tumours can act as adjuvants for humoral immunity</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Frelinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Lord</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="486" to="497" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Crozat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guiton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Contreras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Feuillet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Dutertre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ventre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Vu Manh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Baranek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Storset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Marvel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="page" from="1283" to="1292" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Epidermal and dermal dendritic cells display differential activation and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo</title>
		<author>
			<persName><forename type="first">E</forename><surname>Shklovskaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Roediger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Fazekas De St</surname></persName>
		</author>
		<author>
			<persName><surname>Groth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page" from="418" to="430" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Itano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Mcsorley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Reinhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Ehst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ingulli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Rudensky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Jenkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="47" to="57" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kissenpfennig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Henri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Laplace-Builhe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">´</forename></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Romani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Tripp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Douillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leserman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kaiserlian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="643" to="654" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Bachmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Jennings</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="787" to="796" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Gerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Torabi-Parizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Germain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="172" to="185" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dalod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chelbi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Malissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lawrence</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1104" to="1116" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Targeting dendritic cells-why bother?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kreutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Tacken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Figdor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="2836" to="2844" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Dendritic cell-targeted vaccines-hope or hype?</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kastenm€ Uller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kastenm€ Uller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kurts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Seder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="705" to="711" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance</title>
		<author>
			<persName><forename type="first">V</forename><surname>Flacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Tripp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Mairhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Steinman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stoitzner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Idoyaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Romani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO Mol. Med</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1191" to="1204" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines</title>
		<author>
			<persName><forename type="first">S</forename><surname>Scheiblhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thalhamer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weiss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin. Drug Deliv</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="761" to="773" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">STINGdependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Fuertes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Corrales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spranger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Furdyna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Duggan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Fitzgerald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="830" to="842" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Klarquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Hennies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Lehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Reboulet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Feau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Janssen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Immunol</title>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope unit="page" from="6124" to="6134" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Dissecting the tumor myeloid compartment reveals rare activating antigenpresenting cells critical for T cell immunity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Broz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Binnewies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Boldajipour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pollack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Erle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Rosenblum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Daud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Barber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="638" to="652" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors</title>
		<author>
			<persName><forename type="first">L</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Burnette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">D</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mauceri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Beckett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Darga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="843" to="852" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Tissue-tropic effector T cells: generation and targeting opportunities</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Agace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Immunol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="682" to="692" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bachem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uttler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hartung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ebstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tannert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Salama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Movassaghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Opitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Mages</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="page" from="1273" to="1281" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Jongbloed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kassianos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Angel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Dunbar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Wadley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Jeet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Med</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="page" from="1247" to="1260" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schlitzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mcgovern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Teo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zelante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Atarashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Low</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>See</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Wasan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="970" to="983" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
